Lisata Therapeutics, Inc. develops investigational therapies for advanced solid tumors and other serious diseases. Its principal product candidate, certepetide, is a proprietary iRGD cyclic peptide designed to activate an uptake pathway that can improve tumor targeting and penetration by co-administered or tethered anti-cancer agents.
Recurring Lisata news covers clinical and preclinical data involving certepetide, collaborations and license agreements tied to antibody-drug conjugates and other delivery technologies, development-rights changes for regional markets, financial results, business updates, and corporate matters affecting governance or capital structure.
Lisata Therapeutics (Nasdaq: LSTA) highlighted positive preclinical results on November 4, 2025 after Catalent presented data at the 16th Annual World ADC San Diego Conference (Nov 3–6, 2025).
Catalent reported that incorporating Lisata’s proprietary iRGD cyclic peptide certepetide as a non-cytotoxic payload in its SMARTag® ADC platform improved tumor-selective penetration and broadened intratumoral distribution of cytotoxic payloads, and also enhanced ADC efficacy in preclinical models. Lisata emphasized this finding as supportive of its licensing partnership with Catalent and its strategy to use certepetide to boost therapeutic delivery across modalities.
Lisata Therapeutics (Nasdaq: LSTA) will report third quarter 2025 financial results for the period ended September 30, 2025 on Thursday, November 6, 2025 after market close.
The company will host a conference call at 4:30 p.m. Eastern time the same day. Participants are encouraged to dial in 10 minutes early. Dial-in numbers: toll-free (800) 715-9871, toll/intl (646) 307-1963 with Conference ID 6375221. A live webcast will be available under the Investors & News section of Lisata’s website, with a replay posted two hours after the call and accessible for 12 months.
Lisata Therapeutics (NASDAQ:LSTA) will present a corporate overview at LD Micro Main Event XIX in San Diego, California, taking place October 19–21, 2025. David J. Mazzo, Ph.D., President and CEO, is scheduled to present on Monday, October 20 at 10:30 a.m. PT. One-on-one investor meetings will be held throughout the conference. The presentation will be available for online viewing and interested parties can request meeting information or schedule a one-on-one by emailing jmenditto@lisata.com.
Lisata Therapeutics (Nasdaq: LSTA) and Catalent announced on October 8, 2025 a global, non-exclusive license allowing Catalent to incorporate Lisata’s certepetide and analogs into ADCs developed with Catalent’s SMARTag® platform.
Catalent gains worldwide rights to evaluate certepetide as SMARTag® payloads across multiple ADCs and may partner third parties. Lisata is eligible for over $10 million in tiered study-initiation milestone payments plus revenue sharing on future sales and partnerships. Catalent’s preclinical data provide proof-of-concept that iRGD peptides can improve ADC efficacy and pharmacokinetics; related preclinical work will be highlighted at the November World ADC conference in San Diego.
Lisata Therapeutics (Nasdaq: LSTA) reported encouraging preliminary results from the pancreatic cancer (PDAC) cohort of its Phase 1/2a CENDIFOX trial, evaluating certepetide in combination with FOLFIRINOX-based therapies. The trial, led by Dr. Anup Kasi at KU Cancer Center, showed promising outcomes in treating resectable and borderline resectable PDAC.
Key findings from the 35-patient PDAC cohort include: 50% R0 resection rate and 70% pathologic partial response among the 10 patients who completed pre-surgical therapy. The study demonstrated a 60% two-year overall survival rate and 12-month median disease-free survival. Importantly, the combination therapy showed enhanced immune cell infiltration and increased expression of immune markers, suggesting potential transformation of pancreatic tumors from "immune-cold" to "immune-hot."
Lisata Therapeutics (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing therapies for advanced solid tumors and serious diseases, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.
The company's President and CEO, David J. Mazzo, Ph.D., will deliver a pre-recorded corporate overview presentation, which will be available on-demand starting September 5, 2025, at 7:00 a.m. ET. The conference is scheduled to take place in New York City from September 8-10, 2025.
Lisata Therapeutics (NASDAQ:LSTA) reported Q2 2025 financial results and provided updates on its clinical development portfolio. The company's lead candidate certepetide showed positive preliminary results in multiple clinical trials for advanced solid tumors. Key financial metrics include $22.0 million in cash and equivalents, with runway extending into Q4 2026.
Notable developments include positive preliminary data from the ASCEND trial for pancreatic cancer and the iLSTA trial. The company reported Q2 2025 revenue of $70,000 and reduced operating expenses to $4.9 million, down 10.6% year-over-year. A new USPTO patent extends certepetide's protection until March 2040.
Lisata Therapeutics (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing therapies for advanced solid tumors and serious diseases, will release its Q2 2025 financial results on Thursday, August 7, 2025, after market close.
The company will host a conference call at 4:30 p.m. Eastern time. Participants must pre-register to receive dial-in details and are encouraged to join 15 minutes before the start time. A live webcast will be available on Lisata's website, with a 12-month replay option.
Lisata Therapeutics (Nasdaq: LSTA) announced the completion of patient enrollment in their Phase 1b/2a iLSTA trial, evaluating certepetide in combination with standard-of-care chemotherapy and immunotherapy for locally advanced non-resectable pancreatic ductal adenocarcinoma (PDAC).
The trial's preliminary data, presented at ESMO-GI 2025, showed remarkable results: an overall response rate of 60% and a disease control rate of 100%. Of the 20 participants, 13 showed partial response, 1 exhibited complete response, and 6 demonstrated stable disease. Additionally, 16 out of 20 participants experienced decreased CA19-9 levels, with 7 showing >90% reduction.
The study, conducted at St John of God Subiaco Hospital in Australia, divided participants into three cohorts, with the largest group (Cohort 3, n=20) receiving the full combination therapy of chemotherapy, durvalumab, and certepetide.
Lisata Therapeutics (Nasdaq: LSTA) has secured a new composition of matter patent for certepetide from the USPTO, extending protection until March 2040 with potential for further extension. The patent (U.S. Patent No. 12,351,653) covers certepetide's chemical structure, pharmacokinetic properties, manufacturing methods, and applications for treating solid tumor cancers.
This strategic development provides Lisata with the strongest form of IP protection, preventing others from manufacturing or selling the drug. CEO David J. Mazzo emphasized that this patent milestone enhances certepetide's commercial value by delaying generic competition and strengthens the company's position in potential partnership negotiations.